X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
ProLectin-M (galactomannan) is a precise chemistry based molecule that binds to galectin like receptors on the N terminal of S1 subunit of the Sars-CoV2 virus. It is being evaluated for the treatment of COVID-19.
Lead Product(s): Galactomannan
Therapeutic Area: Infections and Infectious Diseases Product Name: Prolectin-M
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 21, 2024
Details:
ProLectin-M (galactomannan) is a chewable polysaccharide tablet for the treatment of mild to moderate and early stage COVID-19 Patients. The trial’s objective is to provide guidance for a 408 patient Phase III trial.
Lead Product(s): Galactomannan
Therapeutic Area: Infections and Infectious Diseases Product Name: ProLectin-M
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2023
Details:
ProLectin-M (galactomannan) is a chewable polysaccharide tablet for the treatment of mild to moderate and early stage COVID-19 Patients. The trial’s objective is to provide guidance for a 408 patient Phase III trial.
Lead Product(s): Galactomannan
Therapeutic Area: Infections and Infectious Diseases Product Name: ProLectin-M
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Alke Research Private Limited
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 08, 2023
Details:
The proceeds will help to start the dosage optimization study for mild to moderate COVID-19, which has already received the regulatory approval to proceed with dosing of ProLectin-M, an oral galectin antagonist that prevents the entry of the SARS-CoV-2 virus into human cells.
Lead Product(s): Galactomannan
Therapeutic Area: Infections and Infectious Diseases Product Name: ProLectin M
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Triton Funds
Deal Size: $0.5 million Upfront Cash: Undisclosed
Deal Type: Financing June 12, 2023
Details:
ProLectin-M having galactomannan, is a new class of antiviral drug designed to antagonize galectins implicated in inflammatory, fibrotic, and malignant diseases.
Lead Product(s): Galactomannan
Therapeutic Area: Infections and Infectious Diseases Product Name: ProLectin-M
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
